Key clinical point: Increased mean glycated hemoglobin (A1c) level and A1c variability were associated with a significantly higher risk for diabetes-related complications in patients with type 2 diabetes (T2D).

Major finding: Elevated mean A1c level was associated with a significantly higher risk for urine albumin-to-creatinine ratio [UACR] of >300 mg/g (adjusted hazard ratio [aHR] 1.308; P < .001), any retinopathy (aHR 1.274; P < .001), and advanced retinopathy (aHR 1.237; P = .036); similarly, increased standard deviation of A1c was associated with an increased risk for UACR of >300 mg/g (aHR 1.478; P < .001), doubling of serum creatinine (aHR 2.133; P < .001), and all-cause (aHR 1.880; P < .001) and cardiovascular (aHR 1.431; P = .016) mortality.

Study details: Findings are from a prospective study including 1869 patients with T2D who were followed-up for a median of 9.5 years.

Disclosures: This study was supported by grants from the Taipei Veterans General Hospital. The authors declared no conflicts of interest.

Source: Wu TE et al. Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022 (Sep 2). Doi: 10.1016/j.diabres.2022.110069

Key clinical point: Increased mean glycated hemoglobin (A1c) level and A1c variability were associated with a significantly higher risk for diabetes-related complications in patients with type 2 diabetes (T2D).

Major finding: Elevated mean A1c level was associated with a significantly higher risk for urine albumin-to-creatinine ratio [UACR] of >300 mg/g (adjusted hazard ratio [aHR] 1.308; P < .001), any retinopathy (aHR 1.274; P < .001), and advanced retinopathy (aHR 1.237; P = .036); similarly, increased standard deviation of A1c was associated with an increased risk for UACR of >300 mg/g (aHR 1.478; P < .001), doubling of serum creatinine (aHR 2.133; P < .001), and all-cause (aHR 1.880; P < .001) and cardiovascular (aHR 1.431; P = .016) mortality.

Study details: Findings are from a prospective study including 1869 patients with T2D who were followed-up for a median of 9.5 years.

Disclosures: This study was supported by grants from the Taipei Veterans General Hospital. The authors declared no conflicts of interest.

Source: Wu TE et al. Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022 (Sep 2). Doi: 10.1016/j.diabres.2022.110069

Key clinical point: Increased mean glycated hemoglobin (A1c) level and A1c variability were associated with a significantly higher risk for diabetes-related complications in patients with type 2 diabetes (T2D).

Major finding: Elevated mean A1c level was associated with a significantly higher risk for urine albumin-to-creatinine ratio [UACR] of >300 mg/g (adjusted hazard ratio [aHR] 1.308; P < .001), any retinopathy (aHR 1.274; P < .001), and advanced retinopathy (aHR 1.237; P = .036); similarly, increased standard deviation of A1c was associated with an increased risk for UACR of >300 mg/g (aHR 1.478; P < .001), doubling of serum creatinine (aHR 2.133; P < .001), and all-cause (aHR 1.880; P < .001) and cardiovascular (aHR 1.431; P = .016) mortality.

Study details: Findings are from a prospective study including 1869 patients with T2D who were followed-up for a median of 9.5 years.

Disclosures: This study was supported by grants from the Taipei Veterans General Hospital. The authors declared no conflicts of interest.

Source: Wu TE et al. Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022 (Sep 2). Doi: 10.1016/j.diabres.2022.110069

Key clinical point: Use vs no use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was associated with a lower risk for new-onset stroke (NOS) among patients with type 2 diabetes (T2D), with risk reductions being greater among those receiving concurrent statins, biguanides, thiazolidinediones, and glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Major finding: The risk for NOS was significantly lower among SGLT2 inhibitor users vs nonusers (adjusted hazard ratio [aHR] 0.85; 95% CI 0.82-0.88), with similar results being reported in patients receiving statins (aHR 0.84; 95% CI 0.81-0.86), biguanides (aHR 0.77; 95% CI 0.75-0.79), thiazolidinediones (aHR 0.89; 95% CI 0.85-0.93), and GLP-1 RA (aHR 0.84; 95% CI 0.71-0.98).

Study details: The data come from a retrospective population-based cohort study including 232,101 patients with T2D using an SGLT2 inhibitor who were matched with 464,202 patients with T2D not using an SGLT2 inhibitor.

Disclosures: This study was supported by grants from Chung Shan Medical University Hospital. The authors declared no competing interests.

Source: Lin TK et al. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med. 2022;9:966708 (Aug 9). Doi: 10.3389/fcvm.2022.966708

Key clinical point: Use vs no use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was associated with a lower risk for new-onset stroke (NOS) among patients with type 2 diabetes (T2D), with risk reductions being greater among those receiving concurrent statins, biguanides, thiazolidinediones, and glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Major finding: The risk for NOS was significantly lower among SGLT2 inhibitor users vs nonusers (adjusted hazard ratio [aHR] 0.85; 95% CI 0.82-0.88), with similar results being reported in patients receiving statins (aHR 0.84; 95% CI 0.81-0.86), biguanides (aHR 0.77; 95% CI 0.75-0.79), thiazolidinediones (aHR 0.89; 95% CI 0.85-0.93), and GLP-1 RA (aHR 0.84; 95% CI 0.71-0.98).

Study details: The data come from a retrospective population-based cohort study including 232,101 patients with T2D using an SGLT2 inhibitor who were matched with 464,202 patients with T2D not using an SGLT2 inhibitor.

Disclosures: This study was supported by grants from Chung Shan Medical University Hospital. The authors declared no competing interests.

Source: Lin TK et al. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med. 2022;9:966708 (Aug 9). Doi: 10.3389/fcvm.2022.966708

Key clinical point: Use vs no use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was associated with a lower risk for new-onset stroke (NOS) among patients with type 2 diabetes (T2D), with risk reductions being greater among those receiving concurrent statins, biguanides, thiazolidinediones, and glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Major finding: The risk for NOS was significantly lower among SGLT2 inhibitor users vs nonusers (adjusted hazard ratio [aHR] 0.85; 95% CI 0.82-0.88), with similar results being reported in patients receiving statins (aHR 0.84; 95% CI 0.81-0.86), biguanides (aHR 0.77; 95% CI 0.75-0.79), thiazolidinediones (aHR 0.89; 95% CI 0.85-0.93), and GLP-1 RA (aHR 0.84; 95% CI 0.71-0.98).

Study details: The data come from a retrospective population-based cohort study including 232,101 patients with T2D using an SGLT2 inhibitor who were matched with 464,202 patients with T2D not using an SGLT2 inhibitor.

Disclosures: This study was supported by grants from Chung Shan Medical University Hospital. The authors declared no competing interests.

Source: Lin TK et al. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med. 2022;9:966708 (Aug 9). Doi: 10.3389/fcvm.2022.966708

Key clinical point: In patients with type 2 diabetes (T2D), increased visit-to-visit variability in glycated hemoglobin (A1c) and fasting plasma glucose (FPG) was associated with a higher risk for severe hypoglycemia; however, FPG variability better predicted severe hypoglycemic events than A1c variability.

Major finding: Each standard deviation (SD) increase in the variability in A1c and FPG significantly increased the risk for hypoglycemia requiring any third-party assistance (adjusted hazard ratio [aHR] 1.10 and aHR 1.40, respectively; both P < .01) and hypoglycemia requiring medical assistance (aHR 1.11 and aHR 1.46, respectively; both P < .01). However, FPG variability better predicted severe hypoglycemic events than A1c variability (P < .01).

Study details: Findings are from a post hoc analysis of the ACCORD trial including patients with T2D and a high risk for cardiovascular disease, of which 10,052 and 10,068 patients were included in A1c and FPG variability analyses, respectively.

Disclosures: This study was partly supported by the National Science Foundation of China project. The authors declared no conflicts of interest.

Source: Long C et al. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:975468 (Aug 11). Doi: 10.3389/fendo.2022.975468

Key clinical point: In patients with type 2 diabetes (T2D), increased visit-to-visit variability in glycated hemoglobin (A1c) and fasting plasma glucose (FPG) was associated with a higher risk for severe hypoglycemia; however, FPG variability better predicted severe hypoglycemic events than A1c variability.

Major finding: Each standard deviation (SD) increase in the variability in A1c and FPG significantly increased the risk for hypoglycemia requiring any third-party assistance (adjusted hazard ratio [aHR] 1.10 and aHR 1.40, respectively; both P < .01) and hypoglycemia requiring medical assistance (aHR 1.11 and aHR 1.46, respectively; both P < .01). However, FPG variability better predicted severe hypoglycemic events than A1c variability (P < .01).

Study details: Findings are from a post hoc analysis of the ACCORD trial including patients with T2D and a high risk for cardiovascular disease, of which 10,052 and 10,068 patients were included in A1c and FPG variability analyses, respectively.

Disclosures: This study was partly supported by the National Science Foundation of China project. The authors declared no conflicts of interest.

Source: Long C et al. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:975468 (Aug 11). Doi: 10.3389/fendo.2022.975468

Key clinical point: In patients with type 2 diabetes (T2D), increased visit-to-visit variability in glycated hemoglobin (A1c) and fasting plasma glucose (FPG) was associated with a higher risk for severe hypoglycemia; however, FPG variability better predicted severe hypoglycemic events than A1c variability.

Major finding: Each standard deviation (SD) increase in the variability in A1c and FPG significantly increased the risk for hypoglycemia requiring any third-party assistance (adjusted hazard ratio [aHR] 1.10 and aHR 1.40, respectively; both P < .01) and hypoglycemia requiring medical assistance (aHR 1.11 and aHR 1.46, respectively; both P < .01). However, FPG variability better predicted severe hypoglycemic events than A1c variability (P < .01).

Study details: Findings are from a post hoc analysis of the ACCORD trial including patients with T2D and a high risk for cardiovascular disease, of which 10,052 and 10,068 patients were included in A1c and FPG variability analyses, respectively.

Disclosures: This study was partly supported by the National Science Foundation of China project. The authors declared no conflicts of interest.

Source: Long C et al. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:975468 (Aug 11). Doi: 10.3389/fendo.2022.975468

Key clinical point: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitor (DPP4i) use at discharge was associated with a lower risk for 1-year all-cause mortality and heart failure (HF) readmission in hospitalized patients with HF and type 2 diabetes (T2D) in a superaged society.

Major finding: Overall, 71.91% of patients were ≥75 years old. SGLT2i vs DPP4i significantly reduced the risk for 1-year all-cause mortality (adjusted hazard ratio [aHR] 0.70; 95% CI 0.56-0.89) and HF readmission (aHRk 0.52; 95% CI 0.45-0.61), with findings being similar among very elderly patients (age, ≥75 years).

Study details: Findings are from a retrospective study including patients hospitalized with the first episode of acute HF and T2D, of which 2101 patients with T2D receiving SGLT2i were propensity score-matched with 2101 of those receiving DPP4i.

Disclosures: This work was supported by Labor Research Grants from the Ministry of Health, Labour, and Welfare of Japan. The authors declared no conflicts of interest.

Source: Nakai M et al. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: A comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. Cardiovasc Diabetol. 2022;21:157 (Aug 13). Doi: 10.1186/s12933-022-01586-6

Key clinical point: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitor (DPP4i) use at discharge was associated with a lower risk for 1-year all-cause mortality and heart failure (HF) readmission in hospitalized patients with HF and type 2 diabetes (T2D) in a superaged society.

Major finding: Overall, 71.91% of patients were ≥75 years old. SGLT2i vs DPP4i significantly reduced the risk for 1-year all-cause mortality (adjusted hazard ratio [aHR] 0.70; 95% CI 0.56-0.89) and HF readmission (aHRk 0.52; 95% CI 0.45-0.61), with findings being similar among very elderly patients (age, ≥75 years).

Study details: Findings are from a retrospective study including patients hospitalized with the first episode of acute HF and T2D, of which 2101 patients with T2D receiving SGLT2i were propensity score-matched with 2101 of those receiving DPP4i.

Disclosures: This work was supported by Labor Research Grants from the Ministry of Health, Labour, and Welfare of Japan. The authors declared no conflicts of interest.

Source: Nakai M et al. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: A comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. Cardiovasc Diabetol. 2022;21:157 (Aug 13). Doi: 10.1186/s12933-022-01586-6

Key clinical point: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitor (DPP4i) use at discharge was associated with a lower risk for 1-year all-cause mortality and heart failure (HF) readmission in hospitalized patients with HF and type 2 diabetes (T2D) in a superaged society.

Major finding: Overall, 71.91% of patients were ≥75 years old. SGLT2i vs DPP4i significantly reduced the risk for 1-year all-cause mortality (adjusted hazard ratio [aHR] 0.70; 95% CI 0.56-0.89) and HF readmission (aHRk 0.52; 95% CI 0.45-0.61), with findings being similar among very elderly patients (age, ≥75 years).

Study details: Findings are from a retrospective study including patients hospitalized with the first episode of acute HF and T2D, of which 2101 patients with T2D receiving SGLT2i were propensity score-matched with 2101 of those receiving DPP4i.

Disclosures: This work was supported by Labor Research Grants from the Ministry of Health, Labour, and Welfare of Japan. The authors declared no conflicts of interest.

Source: Nakai M et al. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: A comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. Cardiovasc Diabetol. 2022;21:157 (Aug 13). Doi: 10.1186/s12933-022-01586-6

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors were more effective than other oral antidiabetic drugs (OAD) in reducing glycemic variability in patients with type 2 diabetes (T2D) receiving no concurrent insulin treatment.

Major finding: The mean amplitude of glycemic excursions reduced significantly in patients receiving DPP4 inhibitors vs other OAD (mean difference [MD] −0.69 mmol/L; P < .001), insulin secretagogues (MD −0.92 mmol/L; P < .001), non-secretagogues (MD −0.43 mmol/L; P = .02), sulfonylureas (MD −0.91 mmol/L; P < .001), and sodium-glucose cotransporter-2 inhibitors (MD −0.67 mmol/L; P = .03).

Study details: The data come from a meta-analysis of 14 randomized controlled trials including 855 patients with T2D.

Disclosures: This study was funded by MSD China Holding Co. Ltd. Four authors declared being employees of MSD China, and one author declared being an employee of Merck Sharp & Dohme LLC.

Source: Chai S et al. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:935039 (Aug 9). Doi: 10.3389/fendo.2022.935039

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors were more effective than other oral antidiabetic drugs (OAD) in reducing glycemic variability in patients with type 2 diabetes (T2D) receiving no concurrent insulin treatment.

Major finding: The mean amplitude of glycemic excursions reduced significantly in patients receiving DPP4 inhibitors vs other OAD (mean difference [MD] −0.69 mmol/L; P < .001), insulin secretagogues (MD −0.92 mmol/L; P < .001), non-secretagogues (MD −0.43 mmol/L; P = .02), sulfonylureas (MD −0.91 mmol/L; P < .001), and sodium-glucose cotransporter-2 inhibitors (MD −0.67 mmol/L; P = .03).

Study details: The data come from a meta-analysis of 14 randomized controlled trials including 855 patients with T2D.

Disclosures: This study was funded by MSD China Holding Co. Ltd. Four authors declared being employees of MSD China, and one author declared being an employee of Merck Sharp & Dohme LLC.

Source: Chai S et al. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:935039 (Aug 9). Doi: 10.3389/fendo.2022.935039

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors were more effective than other oral antidiabetic drugs (OAD) in reducing glycemic variability in patients with type 2 diabetes (T2D) receiving no concurrent insulin treatment.

Major finding: The mean amplitude of glycemic excursions reduced significantly in patients receiving DPP4 inhibitors vs other OAD (mean difference [MD] −0.69 mmol/L; P < .001), insulin secretagogues (MD −0.92 mmol/L; P < .001), non-secretagogues (MD −0.43 mmol/L; P = .02), sulfonylureas (MD −0.91 mmol/L; P < .001), and sodium-glucose cotransporter-2 inhibitors (MD −0.67 mmol/L; P = .03).

Study details: The data come from a meta-analysis of 14 randomized controlled trials including 855 patients with T2D.

Disclosures: This study was funded by MSD China Holding Co. Ltd. Four authors declared being employees of MSD China, and one author declared being an employee of Merck Sharp & Dohme LLC.

Source: Chai S et al. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:935039 (Aug 9). Doi: 10.3389/fendo.2022.935039

Key clinical point: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors did not have any significant beneficial effects on cardiac autonomic neuropathy (CAN) indices in patients with type 2 diabetes (T2D).

Major finding: SGLT-2 inhibitors had no significant effect on the low-frequency-to-high-frequency ratio (mean difference [MD] −0.11; P = .36), change in standard deviation of all 5-minute mean normal RR intervals (MD −2.83; P = .23), and change in the square root of the mean of the sum of the squares of differences between adjacent RR intervals (MD −0.14; P = .94).

Study details: Findings are from a meta-analysis of four randomized controlled trials including 247 patients with T2D who were randomly assigned to receive SGLT-2 inhibitors or placebo/active comparator.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Patoulias D et al. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Acta Diabetol. 2022 (Aug 19). Doi: 10.1007/s00592-022-01958-0

Key clinical point: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors did not have any significant beneficial effects on cardiac autonomic neuropathy (CAN) indices in patients with type 2 diabetes (T2D).

Major finding: SGLT-2 inhibitors had no significant effect on the low-frequency-to-high-frequency ratio (mean difference [MD] −0.11; P = .36), change in standard deviation of all 5-minute mean normal RR intervals (MD −2.83; P = .23), and change in the square root of the mean of the sum of the squares of differences between adjacent RR intervals (MD −0.14; P = .94).

Study details: Findings are from a meta-analysis of four randomized controlled trials including 247 patients with T2D who were randomly assigned to receive SGLT-2 inhibitors or placebo/active comparator.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Patoulias D et al. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Acta Diabetol. 2022 (Aug 19). Doi: 10.1007/s00592-022-01958-0

Key clinical point: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors did not have any significant beneficial effects on cardiac autonomic neuropathy (CAN) indices in patients with type 2 diabetes (T2D).

Major finding: SGLT-2 inhibitors had no significant effect on the low-frequency-to-high-frequency ratio (mean difference [MD] −0.11; P = .36), change in standard deviation of all 5-minute mean normal RR intervals (MD −2.83; P = .23), and change in the square root of the mean of the sum of the squares of differences between adjacent RR intervals (MD −0.14; P = .94).

Study details: Findings are from a meta-analysis of four randomized controlled trials including 247 patients with T2D who were randomly assigned to receive SGLT-2 inhibitors or placebo/active comparator.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Patoulias D et al. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Acta Diabetol. 2022 (Aug 19). Doi: 10.1007/s00592-022-01958-0

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045